Ann: Trofinetide successful in Phase 2 trial in Fragile X, page-96

My friend just emailed me this:

"Hottod and 8s having a biggest wang contest?"

With that in mind, I'll have to get back to you when the weather warms up.

In all seriousness, I am happy to compromise and take Lexicon’s market cap this time 5 years ago which was $804 million 47¢ NEU equivalent a share which you highlighted may be a bit more equivalent development pipeline stage wise, rather than the time immediately prior to phase III success I used as a comp.

(Although, I would argue NEU is more advanced than Lexicon was 5 years ago based on some of the items I touched on here: http://hotcopper.com.au/threads/ann...in-fragile-x.2656328/page-88?post_id=16604327).

That being said I would even be happy with Bell Potter's 28¢ a share.

Anyway, good analysis - further highlights the difficulty identifying "perfect fit" peer comparisons in biotech.  I have a WIP worksheet I have populated with a few dozen Australian and US listed biotechs, indications, designations, developmental pipeline stages, etc. I am starting to estimate end markets for the different designations - but haven't done a deeper dive into their balance sheets to calculate EV's yet so thanks for taking the time to do so on AGT, etc.
Have a good one, hottod --

8's